Ho BL, et al. - In this prospective, multicenter registry study, researchers assessed the safety and persistence of dabigatran after co-medication with statins. Participants in the study were stroke patients with nonvalvular atrial fibrillation (NVAF) who started dabigatran therapy within 3 months after a clinically evident ischemic cerebrovascular event between 2013 and 2017. A total of 652 patients followed dabigatran therapy for one year. According to findings, co-prescription with a statin was related to a lower risk of bleeding complications for secondary prevention of stroke in patients with NVAF who were taking dabigatran etexilate [a direct thrombin inhibitor that clinicians increasingly prescribe to prevent stroke in patients with NVAF].